Spectral Medical (TSE:EDT) has released an update.
Spectral Medical Inc. has announced significant progress in their Tigris trial for the treatment of septic shock, with 132 patients enrolled as of September 2024 and nearing the target enrollment for the study’s completion by year end. The company is advancing a novel therapeutic device, PMX, which has shown promise in treating septic shock and is seeking FDA approval.
For further insights into TSE:EDT stock, check out TipRanks’ Stock Analysis page.
